Orbactiv sales history revenue
WebNov 11, 2014 · On August 6, 2014, the FDA announced approval of Orbactiv (oritavancin) injection for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by species of Streptococci, Enterococcus faecalis, and Staphylococcus aureus, including methicillin-resistant strains of Staphylococcus aureus. 1,2 Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin. The U.S. Food and Drug Administration (FDA) and … See more Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It … See more Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as See more Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in … See more In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) caused by Gram-positive bacteria. The primary endpoints of … See more • "Oritavancin". Drug Information Portal. U.S. National Library of Medicine. See more
Orbactiv sales history revenue
Did you know?
WebFeb 25, 2024 · ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1,200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg vials. WebSales Leadership & Product Market Growth - Increased Orbactiv utilization by 270 units in 2016 verses 2015 for an increase of $783k and total Orbactiv sales revenue of $2.1 million;...
WebRevenue Collections (Formerly known as Business License User Fee Department) The Department of Revenue Collections collects revenues totaling more than $59 million per … WebAug 7, 2014 · ORBACTIV approval is based on the results of the SOLO I and SOLO II clinical studies which were randomized, double-blind, multicenter trials that evaluated a single 1200 mg IV dose of ORBACTIV for ...
WebFeb 20, 2014 · Orbactiv FDA Approval History. FDA Approved: Yes (First approved August 6, 2014) Brand name: Orbactiv Generic name: oritavancin Dosage form: Injection Company: The Medicines Company Treatment for: Skin and Structure Infection Orbactiv (oritavancin) is a semi-synthetic lipoglycopeptide antibiotic for the treatment of acute bacterial skin and … WebORBACTIV infusion in patients with a history of glycopeptide allergy. In the Phase 3 ABSSSI clinical trials, the median onset of hypersensitivity reactions in ORBACTIV-treated patients was 1.2 days and the median duration of these reactions was 2.4 days. [see Adverse Reactions (6.1)] 5.4 . Infusion Related Reactions
Web2.2 Preparation of ORBACTIV for Intravenous Infusion . ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg …
WebORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture … cshell length of stringWebSep 3, 2024 · The empirical formula of oritavancin diphosphate is C86H97N10O26Cl3•2H3PO4 and the molecular weight is 1989.09. ORBACTIV is supplied as a sterile white to off-white lyophilized powder for intravenous infusion that contains oritavancin diphosphate, mannitol (an inactive ingredient) and phosphoric acid (to adjust … cshell ld_library_pathWebFeb 22, 2024 · Orbactiv (oritavancin) for injection is an antibiotic used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram -positive microorganisms: Staphylococcus aureus (including methicillin -susceptible and methicillin-resistant isolates), Streptococcus pyogenes, … eage check cashing new carrolotn mdWebNov 29, 2024 · U.S. combined net sales of Minocin IV and Orbactiv On net sales at or below $100 million = 5.0% On net sales above $100 million = 15.0% Ex-U.S. combined net sales … eagegawWeboritavancin (Rx) Brand and Other Names: Kimyrsa, Orbactiv Classes: Glycopeptides Dosing & Uses AdultPediatric Dosage Forms & Strengths injection, lyophilized powder for reconstitution... c shell languageWebOrbactiv (oritavancin) is an antibiotic. It fights against certain bacteria called Gram-positive bacteria. The medication works by preventing the bacteria from making their protective … eage event calendarWebOverview This is a summary of the European public assessment report (EPAR) for Tenkasi (previously Orbactiv). It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tenkasi. eageeage